Drug Approval | March 22, 2022
Merck’s Keytruda approved for fourth gynecologic cancer indication
The approval is based on new data from cohorts D and K of the KEYNOTE-158 trial
The approval is based on new data from cohorts D and K of the KEYNOTE-158 trial
Prof. Kypros has revolutionised the field of fetal medicine through his extensive research and medical practice achievements, including introducing intrauterine blood transfusions for fetal anaemia
Expanded capabilities across pharma services network accelerate innovation and enhance productivity for customers
The Centre will be instrumental in streamlining vaccination resources and facilitate equitable access to safe and efficacious COVID-19 vaccines
All of Us Research Program releases genomic data to researchers, combined with participant-generated data collected on Vibrent Health’s research platform
In a Nature Communications Medicine publication, the Verita proprietary platform detected 96 per cent of stage 1 pancreatic cancers and three-quarters of stage 1 ovarian cancers using isolated exosomes and AI-enabled protein marker analysis
Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab
First approved in 2019, Rinvoq is a JAK inhibitor approved for four indications across gastroenterology, dermatology and rheumatology
The facility will enable research initiatives in analytical chemistry, biopharmaceuticals, and life sciences
This drug-device combination product is a metered-dose inhaler (MDI), which contains both budesonide (a corticosteroid that reduces inflammation) and formoterol (a long-acting bronchodilator that relaxes muscles in the airways to improve breathing)
Subscribe To Our Newsletter & Stay Updated
